ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 162 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $22,243 | -77.1% | 13,989 | -10.2% | 0.00% | – |
Q4 2022 | $97,082 | +10.3% | 15,583 | +20.4% | 0.00% | – |
Q3 2022 | $88,000 | +15.8% | 12,940 | +7.9% | 0.00% | – |
Q2 2022 | $76,000 | -6.2% | 11,992 | -30.8% | 0.00% | – |
Q1 2022 | $81,000 | +62.0% | 17,332 | +73.1% | 0.00% | – |
Q4 2021 | $50,000 | -80.1% | 10,015 | -15.7% | 0.00% | -100.0% |
Q2 2021 | $251,000 | -16.9% | 11,875 | +10.1% | 0.00% | 0.0% |
Q1 2021 | $302,000 | +15.7% | 10,783 | +7.5% | 0.00% | 0.0% |
Q4 2020 | $261,000 | -8.4% | 10,035 | +31.1% | 0.00% | 0.0% |
Q3 2020 | $285,000 | -30.0% | 7,655 | -3.5% | 0.00% | -50.0% |
Q2 2020 | $407,000 | -26.9% | 7,932 | -15.1% | 0.00% | -33.3% |
Q4 2019 | $557,000 | +48.9% | 9,341 | -8.4% | 0.00% | +50.0% |
Q3 2019 | $374,000 | -21.8% | 10,194 | -0.8% | 0.00% | -33.3% |
Q2 2019 | $478,000 | +2.6% | 10,279 | -11.4% | 0.00% | 0.0% |
Q1 2019 | $466,000 | -11.9% | 11,600 | +0.9% | 0.00% | -25.0% |
Q4 2018 | $529,000 | -13.1% | 11,498 | -16.3% | 0.00% | 0.0% |
Q3 2018 | $609,000 | +8.9% | 13,730 | -3.8% | 0.00% | 0.0% |
Q2 2018 | $559,000 | -46.6% | 14,271 | -1.3% | 0.00% | -42.9% |
Q1 2018 | $1,046,000 | -4.5% | 14,463 | -13.0% | 0.01% | -12.5% |
Q4 2017 | $1,095,000 | +39.7% | 16,631 | +6.3% | 0.01% | +14.3% |
Q3 2017 | $784,000 | +31.1% | 15,640 | +21.1% | 0.01% | +16.7% |
Q2 2017 | $598,000 | +23.8% | 12,912 | -5.7% | 0.01% | +20.0% |
Q1 2017 | $483,000 | +124.7% | 13,686 | -20.4% | 0.01% | +150.0% |
Q4 2016 | $215,000 | -0.9% | 17,198 | +10.0% | 0.00% | -33.3% |
Q3 2016 | $217,000 | +18.6% | 15,634 | -15.6% | 0.00% | +50.0% |
Q2 2016 | $183,000 | -40.8% | 18,533 | +1.3% | 0.00% | -50.0% |
Q1 2016 | $309,000 | -30.7% | 18,295 | -8.6% | 0.00% | -20.0% |
Q4 2015 | $446,000 | +85.8% | 20,020 | +104.3% | 0.01% | +66.7% |
Q3 2014 | $240,000 | +30.4% | 9,800 | -15.6% | 0.00% | +50.0% |
Q2 2014 | $184,000 | -25.8% | 11,611 | -29.1% | 0.00% | -33.3% |
Q1 2014 | $248,000 | – | 16,385 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Boxer Capital, LLC | 1,275,000 | $45,020,000 | 9.84% |
Aviva Holdings Ltd. | 340,100 | $12,009,000 | 5.60% |
Aisling Capital LLC | 837,125 | $29,559,000 | 5.38% |
RA Capital Management | 704,701 | $24,883,000 | 3.05% |
Rhenman & Partners Asset Management AB | 543,347 | $19,186,000 | 3.04% |
BB BIOTECH AG | 1,408,542 | $49,736,000 | 1.63% |
Antipodean Advisors LLC | 91,000 | $3,213,000 | 1.57% |
Iguana Healthcare Management, LLC | 75,000 | $2,648,000 | 1.31% |
Crawford Lake Capital Management, LLC | 93,551 | $3,303,000 | 1.31% |
FT Options LLC | 22,834 | $806,000 | 1.06% |